The co-packaged medication is indicated for the treatment of mild-to-moderate COVID-19 in people aged twelve years of age and older weighing at least with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. If administered within five days of symptom onset, the efficacy of the co-packaged medication against hospitalization or death in adults is about . In the European Union, the co-packaged medication is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. The co-packaged medication is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19.
Nirmatrelvir/ritonavir
Atazanavir/ritonavir
Atazanavir/cobicistat
Darunavir/cobicistat
Cabotegravir/rilpivirine
Ombitasvir/paritaprevir/ritonavir
Abacavir/lamivudine
Dolutegravir/rilpivirine